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OBJECTIVES: Endocrine therapies in the treatment of breast
cancer include tamoxifen, and aromatase inhibitors such as anas-
trozole. Anastrozole has demonstrated superior efﬁcacy over
tamoxifen in reducing disease recurrence in an EBC population
and is associated with a number of important tolerability bene-
ﬁts over tamoxifen. This study aimed to examine the differences
in preferences between anastrozole and tamoxifen as adjuvant
treatment for breast cancer. METHODS: Eighty-ﬁve women
aged 50–83 (mean 61) years were recruited from the Australian
general public. Participants completed questions regarding expe-
rience with breast cancer and undertook a discrete choice task.
The attributes used in the WTP scenarios included values for risk
of breast cancer recurrence, hot ﬂushes, vaginal abnormalities,
and cardiovascular events (in favour of anastrozole) and mus-
culoskeletal disorders and fracture (in favour of tamoxifen), and
cost. The risk estimates were derived from clinical sources.
RESULTS: A total of 74 subjects provided evaluable data. Eleven
subjects were excluded because they were non-traders (3) or irra-
tional in their choice task. The total WTP for anastrozole over
tamoxifen was $AUS673.40 per month (95% CI: 390.6–1044.0)
for 3–5 years. This included a WTP of AUS$267.00,
AUS$237.10 and AUS$276.90 for the reduced risk associated
with anastrozole for breast cancer recurrence, vaginal abnor-
malities and cardiovascular events, respectively. For the reduced
risk of musculoskeletal disorders and fractures associated with
tamoxifen, a negative WTP of -AUS$67.80 was obtained. A neg-
ative point estimate was obtained for hot ﬂushes (-AUS$39.80).
CONCLUSIONS: On average, subjects were willing to pay
AUS$673.40 per month for 3–5 years for the attributes of anas-
trozole over tamoxifen, placing higher value on reduced risk of
recurrence, vaginal abnormalities and cardiovascular disease
than hot ﬂushes, musculoskeletal disorder and fracture.
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OBJECTIVES: Colorectal cancer is one of the most common
forms of cancer in Europe and the USA. The aim of this study
was to assess prospectively changes of quality of life after surgery
for rectal cancer with a focus on sexuality and gender related
differences. METHODS: Since 1998, the EORTC-QLQ-C-30
and a tumor speciﬁc ad-hoc module were prospectively admin-
istered to patients before surgery, at discharge, 3, 6, 12 and 24
months postoperatively. These data were combined with QoL
data from a historical cohort of patients that underwent surgery
between 1992 and 1997. Altogether, 819 patients with rectum
and sigma carcinoma were included in the analysis, 541 of them
provided QoL data for at least 1 time point. Comparisons were
made between female and male patients. Due to skewed distrib-
utions, non-parametric statistical analyses were performed. A
global alpha of p < 0.05 was considered signiﬁcant. RESULTS:
In total, 262 female and 279 male patients provided QoL data.
Both groups were comparable in terms of age, tumor stage and
surgical procedure. In men as well as women most QoL scores
dropped signiﬁcantly below baseline in the early postoperative
period. From the third month onwards, global health, emotional
and physical functioning improved. Female gender was associ-
ated with signiﬁcantly worse global health and physical func-
tioning and with higher scores on treatment strain and fatigue.
Men reported more difﬁculties with sexuality. These problems
tended to remain. CONCLUSIONS: These ﬁndings conﬁrm that
QoL changes post surgery and is different between men and
women. Women appear to be affected by impaired physical func-
tioning and global health. Female gender is associated with sig-
niﬁcantly higher fatigue levels and increased strain values after
surgery. In terms of impaired sexual enjoyment, men are put
more under strain than woman. All differences between men and
women remain stable in the course of time.
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OBJECTIVES: Prostate cancer is one of the most common forms
of cancer in Europe and the USA. Predominant symptoms in
these patients are erectile dysfunctions and urinary problems.
Since decreases of these functions can be attributed to disease
and treatment but also to age, we studied a German reference
population measuring as well general QoL as prostate speciﬁc
symptoms. Data from this study can be used as control group in
studies with older men treated for prostate cancer. METHODS:
In cooperation with a German health insurance company 3000
questionnaires were mailed to a randomly selected sample of
men aged 45–75 years. General and disease targeted health
related quality of life was measured using the EORTC QLQ-
C30, a recently validated prostate speciﬁc module, the EQ-5D
and the Patient Oriented Prostate Utility Score (PORPUS). A
total of 1129 (37.6%) questionnaires were returned. We com-
pared QoL data from this new reference population to QoL data
from a historical cohort of 950 patients following prostatectomy
or radio therapy, in which the same set of questionnaires was
used. RESULTS: Mean age was 56.8 years. In terms of general
QoL (QLQ-C30), the reference population showed similar QoL
scores as prostatectomy patients but better scores than radio
therapy patients. On the prostate speciﬁc module, the reference
sample showed better QoL but a high extent of erectile dys-
function, urinary problems and psychic strain. More than 1/3 of
the patients (39.0%) from the reference population reported
some degree of urinary problems, 63.2% reported a decrease of
sexual activity. CONCLUSIONS: Taking into account the sensi-
tive topic of this study, a response rate of 37.6% is more than
satisfying. Older men in our randomly selected, population based
sample do not show perfect erectile and urinary function. These
ﬁndings should be kept in mind when interpreting QoL data of
prostate cancer patients.
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OBJECTIVES: Cost of management of toxicity associated with
chemotherapy can be considerable. We estimated costs of treat-
ing drug-related adverse events associated with pemetrexed or
docetaxel as second-line therapy for non-small cell lung cancer
(NSCLC). METHODS: Resource utilisation (RU) data (hospital
admissions, concomitant medications, transfusions) were col-
lected prospectively during a multinational, randomised phase III
trial comparing pemetrexed 500mg/m2 and docetaxel 75mg/m2,
